LifeMine Therapeutics is reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics to address previously intractable therapeutic challenges. LifeMine’s drug discovery engine enables large-scale genomic search and retrieval of small molecule drug candidates that have a highly specific function. Through its discovery engine and proprietary fungal strain collections, LifeMine has discovered, in genomic space, hundreds of potentially high-impact drug candidates relevant to targets across all major disease areas, and has an initial focus on highly impactful precision medicines in oncology and immune modulation. The Company was founded in 2017 by renowned entrepreneur/scientists Gregory Verdine, Ph.D. and Richard Klausner, M.D., and entrepreneur/company-builder WeiQing Zhou, M.B.A. Headquartered in Cambridge, MA, and with a second site at Gloucester Harbor, MA, LifeMine has raised more than $120 million from leading life science investors.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $280M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | 6 Dimensio... | 6dimension... |
| - | MRL Ventur... | mrlv.com |
| - | GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 15.04.2022 | Series C | $175M | - |
| 07.01.2021 | Series B | $50M | - |
| 19.09.2017 | Series A | $55M | ARCH Ventu... |
Mentions in press and media 10
| Date | Title | Description |
| 23.03.2022 | LifeMine Therapeutics Snags $175M in Series C | CAMBRIDGE, MA, LifeMine Therapeutics, a biopharmaceutical company, announced the completion of a $175M Series C financing led by Fidelity Management & Research Company. >> Click here for more funding data on LifeMine Therapeuti... |
| 07.01.2021 | LifeMine Therapeutics Raises $50 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 millio... |
| 07.01.2021 | LifeMine Therapeutics Announces $50 Million Series B Financing | LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading l... |
| 16.05.2018 | FogPharma Secures $66 Million Series B Financing | FogPharma today announced the closing of a $66 millionSeries B financing. The round was led by 6 Dimensions Capital, with participation by additional new investors, including GV (formerly Google Ventures), Blue Pool Capital, Horizons Ventur... |
| 19.09.2017 | Term Sheet — Tuesday, September 19 | VCs VERSUS ICOs Companies have raised more than $1.7 billion through initial coin offerings this year, surpassing early-stage VC funding for Internet companies. It’s easy to see why an ICO is appealing to tech founders (No due diligence! LO... |
| 19.09.2017 | China’s Wuxi Healthcare Ventures leads $55m Series A in US-based LifeMine Therapeutics | Premium Chinese investment firm Wuxi Healthcare Ventures has led a $55-million series A financing for US-based biotech company LifeMine Therapeutics after earlier investing in its $5 million seed round. Continue reading this story with a su... |
| 18.09.2017 | LifeMine Therapeutics Closes $55M Series A Financing | LifeMine Therapeutics, a Boston, MA-based drug discovery company, closed a $55m Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch ... |
| 18.09.2017 | Arch Ventures Joins $55M Series A for LifeMine Therapeutics | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |
| 18.09.2017 | LifeMine Therapeutics Launches with $55M Series A | BOSTON, MA, LifeMine Therapeutics today announced the closing of a $55 million Series A financing. >> Click here for more funding data on LifeMine Therapeutics >> To export LifeMine Therapeutics funding data to PDF and Excel... |
| 18.09.2017 | LifeMine Therapeutics Closes $55M Series A | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |